Phase 1 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Women aged 19 years or older at the time of signing the consent form
• People diagnosed with advanced high-grade ovarian cancer that has a BRCA gene mutation
• People who have already been taking olaparib 300 mg (two 150 mg tablets) twice daily by mouth for at least 10 days in a row, OR people whose treating doctor considers a stable dose of olaparib 300 mg twice daily to be appropriate for them
• People with a life expectancy of at least 12 weeks, as estimated by their doctor
• People with a Body Mass Index (BMI) — a measure of body weight relative to height — between 18.50 and 30.00 kg/m² at the time of screening

Who may not be able to join:

• People who have had a serious allergic reaction to olaparib or any of its ingredients
• People currently living with certain serious health conditions, including lung inflammation (pneumonitis), a blood or bone marrow disorder called myelodysplastic syndrome or acute myeloid leukaemia, severe liver disease, an active uncontrolled infection or systemic illness, or active hepatitis B, hepatitis C, HIV, or syphilis
• People who have received radiation therapy within 4 weeks before screening
• People who have received any other anti-cancer treatment within 4 weeks before screening
• People who have had major surgery within 4 weeks before screening, or who have not fully recovered from a previous major surgery
• People who have lost approximately 350 mL of blood or more in the 12 weeks before screening

Important: Always verify eligibility with the trial site directly before applying.